Effects on the Human Body of a Dietary Supplement Containing L-Carnitine and Garcinia cambogia Extract: A Study using Double-blind Tests by Yonei, Yoshikazu et al.
89
Original Article J. Clin. Biochem. Nutr., 42, 89–103, March 2008
JCBN Journal of Clinical Biochemistry and Nutrition 0912-0009 1880-5086 the Society for Free Radical Research Japan Kyoto, Japan jcnb2008014 10.3164/jcbn.2008014 Original Article Effects on the Human Body of a Dietary Supplement Containing 
L-Carnitine and Garcinia cambogia Extract: 
A Study using Double-blind Tests
Yoshikazu Yonei1,*, Yoko Takahashi1, Sawako Hibino1, Miwako Watanabe2, 
and Toshito Yoshioka3
1Anti-Aging Medical Research Center, Doshisha University, Kyoto 610-0394, Japan
2Mareesia Garden Clinic, Tokyo 163-1011, Japan
3Waseda University Graduate School of Commerce, Tokyo 165-8050, Japan
3 2008 ?? 2 2008 42 2 89 103 Received 13.3.2006 ; accepted 20.2.2007
*To whom correspondence should be addressed 
Tel: +81-75-391-5644 Fax: +81-3-5730-1447 
E-mail: yyonei@mail.doshisha.ac.jp
Received 13 March, 2006; Accepted 20 February, 2007
Copyright © 2008 JCBN Summary The effect of a dietary supplement with L-carnitine (600 mg/day) and Garcinia
cambogia extract (500 mg/day as hydroxycitric acid) as main ingredients was studied in 35
healthy volunteers {48.3 ± 6.9 years, body mass index (BMI): 26.3 ± 1.7} in a double-blind test
(18 subjects in the Test Group and 17 in the Control Group). The yearly examination includes
the standard yearly medical tests done in Japan, tests for assessing hormonal age, and a survey
for assessing physical and mental fitness of the subjects, called the Anti-Aging QOL Common
Questionnaire (AAQol). Use of this supplement significantly improved the level of lipid
peroxides (−12.8%) in the blood as well as physical symptoms such as “tired eyes,” “blurry
eyes,” “muscle pain/stiffness,” “early satiety,” “epigastralgia,” “dizziness,” “arthralgia” and
“easily breaking into a sweat.” The Control Group showed a significantly favorable improve-
ment rate, especially for “dizziness.” On the other hand, groups of subjects using the test
compounds saw a significant rise in total cholesterol (4.5%), fasting blood sugar (4.1%) and
HbA1c (3.4%). Our findings suggest that the consumption of the supplement can reduce the
oxidative damage; however, the effect on QOL was equivocal. Garcinia cambogia extract did
not show dietary efficacy.
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Introduction
The objective of anti-aging medicine is to live as long as
possible in good health. It is medical treatment that not only
prolongs human life, but also enables a person to live a
healthy and happy life, maintain quality of life (QOL), and
reduce the physical and mental deterioration of aging [1].
Medically, anti-aging medicine is classified as prophylactic
medicine. Checkups and screenings for assessing the degree
of aging are offered in Japan; a range of treatment options is
available including diet, exercise, other lifestyle therapies,
and drug therapies including nutritional supplement therapies
and hormone replacement therapies.
Terms such as integrated medicine, alternative healthcare,
Chinese herbal medicine, acupuncture therapy, and anti-
aging medicine have been discussed in recent years, and
numerous treatment methods are being proposed that differ
from conventional Western medicine. Although numerous
reports cite the efficacy of such treatment methods, the
parameters used differ from one study to another. General
physicians are currently left with the basic question, “ToY. Yonei et al.
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what degree are these treatments effective, and for what
types of symptoms and diseases?”
The authors have used common parameters to investigate
and study (a) the assessments of general physical examina-
tions, (b) the physical and psychological influence as well as
safety of dietary supplements, health foods, medical devices,
exercise equipment, and cosmetics, and (c) obesity [2–4].
Our findings are shedding more light on the efficacies,
limitations, and the range of effects of these products.
Amino acids, in particular, exert a variety of influences on
the body, and we have therefore conducted studies on health
foods containing amino acids. In this study, we have focused
on a food product for which one manufacturer has made
health claims; the product contains L-carnitine, a type of
amino acid, and Garcinia cambogia extract (65% hydroxy-
citric acid) manufactured by Nurex Corporation, Osaka;
hereinafter referred to as “the Product”. We studied, using
healthy middle-aged and older subjects, the effects of the
Product on the body as a double-blind, non-cross-matching
test. We also studied parameters that are deemed especially
important to anti-aging medicine, for the purpose of deter-
mining whether or not the use of the Product enhances QOL
in people aged in their 40s to 60s.
Experimental Procedures
Subjects
The subjects of our study were healthy individuals aged
in their 40s to 60s, with a BMI of 24 or higher, who had
provided us with their written consent to participate in this
study. The following individuals were excluded:
•  those taking hormones, anti-osteoporosis drugs, and
other medications
•  those with diabetes, marked hepatic dysfunction, or
other chronic diseases
•  those with severe liver, kidney, heart, and/or blood
diseases and other complications
•  other individuals judged by a physician as unfit to
participate in the study
Prior to the start of the test, we provided potential test
subjects a thorough explanation not only of the duration,
place, content, and methods of the test, but also on the
benefits anticipated to be gained from participating in the
study as well as disadvantages that may occur. The test
subjects were assured that participation was completely
voluntary, and that they would not suffer any disadvantages
whatsoever, if they decided mid-way to withdraw from the
testing, for any reason. The method of taking the Product
was explained to all test participants by Nurex Corporation,
either in writing or by holding an explanatory meeting. 
Design
The period of the test was determined to be 8 weeks from
October 3 to November 28, 2004. Before and after the test,
the following items were measured at the Mareesia Garden
Clinic, Tokyo.
•  physical measurements: Height (cm), weight (kg), body
fat percentage, systolic and diastolic blood pressures
and others
•  blood tests: Platelet count (104/µl), erythrocyte count
(RBC, 104/µl), leukocyte count (WBC, /µl), hemo-
globin content (HGB, g/dl), hematocrit (HCT, %),
glutamate-oxaloacetate transaminase, glutamate-
pyruvate transaminase (GOT, GPT, IU/l), γ-glutamyl
transpeptase (γ-GTP, IU/l), alkaline phosphatase (ALP,
IU/l), creatinine phosphokinase (CPK, mU/ml), C-
reactive protein (CRP, mg/dl), blood urea nitrogen
(BUN, mg/dl), blood creatinine (Cr, mg/dl), uric acid
(UA, mg/dl), total cholesterol (T-Chol, mg/dl), HDL-
cholesterol (HDL-C, mg/dl), LDL-cholesterol (LDL-
C, mg/dl), triglycerides (TG, mg/dl), fasting blood
sugar (FBS, mg/dl), glycohemoglobin A1C (HbA1c),
lactic acid (mg/dl), cortisol, dehydroepiandrosterone
sulfate (DHEA-s), IGF-I, insulin, lipid peroxides (LPO,
nmol/ml), electrolytes: sodium (Na, mEq/l), potassium
(K+, mEq/l), and chloride (Cl−, mEq/l).
• urine tests: Urinary 8-hydroxy-deoxyguanosine (8-
OHdG) and urinary isoprostane
•  observations on improvement of QOL using a common
questionnaire sheet
If circumstances such as the following occurred, necessi-
tating discontinuation of the test, the test was discontinued
immediately, following the decision of the physician in
charge of the test, and adequate treatment was provided.
•  if other serious diseases are seen to have developed
• if  existing  symptoms  (including complications)
worsened
•  if a physician determines that continuation of the test is
impossible for other reasons
Our present study targeted 35 healthy individuals (18 men
and 17 women) {48.3 ± 6.9 years, body mass index (BMI):
26.3 ± 1.7} who were randomly divided into the Test Group
and the Control Group. At least 6 cases in each group are
necessary for detection of the significant difference in any
of more than 50 items in the Anti-Aging QOL Common
Questionnaire (AAQol) [2–4], and the number should be
doubled or tripled for the classified analysis according to 2
or 3 classes. There were 18 individuals in the Test Group
(age: 48.6 ± 6.0 years, height: 163.1 ± 7.9 cm; weight:
69.9 ± 7.2 kg, and BMI: 26.3 ± 1.7; mean ± SD), and 17 in
the Control Group (age: 48.0 ± 7.9 years, height: 163.5 ±
11.2 cm, weight: 66.5 ± 11.9 kg, and BMI: 24.7 ± 2.9;
mean ± SD). The Test Group took 6 doses of the Product,
including L-carnitine (600 mg/day) and Garcinia cambogia
extract (500 mg/day as hydroxycitric acid) for 8 weeks,
while the Control Group took 6 doses of a placebo drug forCarnitine Use and Improvements in QOL
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8 weeks. The method of taking these test drugs was
explained by a nutritionist to all of the test subjects.
The Product is manufactured by Nurex Corporation of
Osaka Prefecture, Japan, and has the following composition.
Raw materials:
L-carnitine, L-tartrate, Garcinia cambogia extract, corn
starch, edible purified oil-processed fat and oil (hydro-
genated oil), gelatin, caramel coloring, calcium pantoth-
enate, vitamin B1. Nutritional ingredients (for every 3 doses
of the Product): calories: 4.58 kcal, protein: 0.38 g, fat:
0.06 g, carbohydrates: 0.61 g, sodium: 1.26 mg, vitamin B1:
1.2 mg, pantothenic acid: 10 mg, L-carnitine: 300 mg,
hydroxycitric acid (Garcinia cambogia extract): 250 mg.
The amounts of vitamin B1 and pantothenic acid are subtle
compared with those of daily dietary intake.
As indicators for the degree of oxidation stress, we used
serum lipid peroxide, 8-OHdG (8-hydroxy-2' deoxy-
guanosine), and isoprostane (8-isoprostane F-2α) [5–7].
These indicators were measured at the Japan Institute for the
Control of Aging. Moreover, the 8-OHdG, isoprostane, and
creatinine contained in the first urine in the early morning
were measured to calculate the rate of 8-OHdG/CRE ·
isoprostane production and the creatinine correction volume
(8-OHdG/CRE·isoprostane/CRE), based on the volume of
urine and urine collection period (the time from the last
urination of the previous night to the first urination the
following morning).
Subjective symptoms were divided into physical and
mental symptoms and evaluated on a scale of 1 to 5, using
the Anti-Aging QOL Common Questionnaire (AAQol) [2–4].
Statistical analysis
A statistical analysis of the results was performed using
the paired t-test, non-paired t-test, or non-parametric test
(Wilcoxon’s signed rank test). The relationship between
each parameter was tested using Pearson’s correlation
coefficient. A value of p<0.05 was considered to indicate a
statistically significant change. Dr.SPSSII, a software pro-
gram (manufactured by SPSS Inc.) was used in this study.
Results
Test results
Tables 1 and 2 show the physical measurement values.
The Test Group showed no significant changes in height,
weight, body water content, muscle volume, lean muscle
mass, skeletal muscle volume, body fat volume, BMI, body
fat percentage, waist-hip ratio, basal metabolism, or blood
pressure. The Control Group, on the other hand, showed
slightly significant changes in body water content (2.1%,
p = 0.002), muscle volume (2.0%, p = 0.002), lean muscle
mass (2.0%, p = 0.002) and basal metabolism (1.4%,
p = 0.002). We compared the rates before and after the test
between the Test and the Control Groups and saw no signifi-
cant intra-group differences in any of the items.
In the general laboratory tests (Tables 3 and 4), the Test
Group showed significant changes in their total cholesterol
(4.5%) from 214.0 ± 31.1 to 223.7 ± 31.44 (p =0 . 0 4 6 ) ,
fasting blood sugar (4.1%) from 91.9 ± 10.6 to 95.7 ± 7.5
(p = 0.016), and HbA1c (3.4%) from 4.73 ± 0.43 to
4.89 ± 0.39 (p = 0.000). Significant fluctuations were also
seen in MCV (1.4%) from 93.5 ± 3.3 to 94.8 ± 3.2
(p = 0.000) and MCH (1.3%) from 30.6 ± 1.5 to 31.0 ± 1.4
(p = 0.000), but they were slight changes within the range of
1.4%. The Control Group showed significant variations in
the leukocyte count (−10.9%) from 7244.0 ± 2665.9 to
6456.7 ± 2120.0 (p = 0.020) and HbA1c (2.9%) from
4.89 ± 0.40 to 5.03 ± 0.43 (p = 0.001). Although a signifi-
cant fluctuation was seen in MCV (1.0%) from 92.6 ± 5.6 to
93.5 ± 5.7 (p = 0.038), the change was only 1.0%. Intra-
group analysis showed no significant differences between
the two groups.
The Test Group showed no significant variations in lactic
acid, insulin, IGF-I, cortisol, or DHEA-s (Tables 3 and 4).
The Control Group, meanwhile, showed a significant varia-
tion in IGF-I (−8.8%) from 197.9 ± 68.9 to 180.6 ± 60.4
(p = 0.007). An intra-group analysis showed no significant
differences between the two groups.
Regarding oxidation stress markers (Tables 3 and 4), the
Test Group showed a significant reduction in blood lipid
peroxide (−12.8%) from 0.39 ± 0.07 to 0.34 ± 0.08 (p =
0.001) but no significant changes in the speed of urinary
8-OHdG formation, or the speed of isoprostane formation,
8-OHdG/CRE, or isoprostane/CRE. The Control Group, on
the other hand, showed no significant changes in lipid
peroxides, and no significant variations in other urinary
markers. An intra-group analysis showed no significant
differences between the two groups.
Tables 5–8 show the results of the analysis on the Anti-
Aging QOL Common Questionnaire (AAQol). Regarding
physical symptoms, the Test Group showed significant
improvements in scores of the following 8 out of 30 items:
“tired eyes” (p = 0.015), “blurry eyes” (p = 0.035), “muscle
pain/stiffness” (p = 0.017), “early satiety” (p = 0.042), “epi-
gastralgia” (p = 0.010), “dizziness” (p = 0.003), “arthralgia”
(p = 0.037), and “easily breaking into a sweat” (p =0 . 0 2 6 ) .
The Control Group did not show improvements in any of the
scores. Intra-group analysis showed a significant difference
between the two groups in terms of changes in the score for
“dizziness” (p =0 . 0 0 8 ) .
As for mental symptoms, the Test Group showed no items
(of the 21 items) whose scores had improved. The Control
Group showed a significant improvement in the score for a
single item: “sleeping disturbance” (p = 0.019). An intra-
group analysis showed no significant differences between
the two groups.Y. Yonei et al.
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Variations associated with gender
A factoral correlational analysis was performed by gender
and for each item. Results of physical measurements showed
higher values in men for height, weight, body water content,
muscle volume, lean muscle mass, skeletal muscle volume
and basal metabolism. Women had a significantly higher
percentage of body fat. Regarding the lifestyles of subjects,
men showed a significantly higher use of alcoholic drinks
and cigarettes.
Regarding physical symptoms, slightly more men than
women suffered “diarrhea” and “lumbago” (p<0.05), while
more women than men suffered “excessive sensitivity to
cold” (p<0.01). No gender differences were seen in mental
symptoms.
Regarding general laboratory test items, men showed
significantly higher values than women in their erythrocyte
Table 1. Physical measurements of Test Group
n = 18, mean ± SD, paired t test or Mann-Whitney U test
Unit Before 8 weeks later
P value vs 
“before” value
P value vs 
Control Group
Height kg 163.1 ± 7.9 163.2 ± 7.8 0.348 0.846
Weight kg/m2 69.9 ± 7.2 70.1 ± 7.0 0.439 0.964
Total body water L 33.8 ± 5.9 34.4 ± 5.5 0.083 0.983
Muscle volume cm 46.2 ± 8.0 47.0 ± 7.5 0.079 0.983
Lean body weight kg 48.9 ± 8.4 49.8 ± 7.8 0.084 0.984
Skeletal muscle volume kg 26.4 ± 5.3 26.5 ± 4.9 0.667 0.597
Body fat amount kg 21.0 ± 3.9 20.5 ± 3.7 0.238 0.977
BMI 26.3 ± 1.7 26.3 ± 1.7 0.643 0.999
Body fat percentage % 29.8 ± 6.5 29.4 ± 6.0 0.652 0.614
Waist/hip ratio 0.92 ± 0.04 0.91 ± 0.04 0.331 0.797
Basal metabolism kcal 1315.8 ± 175.2 1331.3 ± 166.9 0.094 0.965
Systolic pressure mmHg 126.9 ± 12.0 125.9 ± 12.1 0.608 0.665
Diastolic pressure mmHg 83.4 ± 7.7 81.6 ± 8.2 0.275 0.972
Table 2. Physical measurements of Control Group
n = 17, mean ± SD, paired t test or Mann-Whitney U test
Unit Before 8 weeks later
P value vs 
“before” value
P value vs 
Test Group
Height kg 163.6 ± 11.2 163.5 ± 11.2 0.924 0.846
Weight kg/m2 66.5 ± 11.9 66.6 ± 12.2 0.714 0.964
Total body water L 33.8 ± 7.8 34.5 ± 7.8 0.002 0.983
Muscle volume cm 46.1 ± 10.6 47.0 ± 10.6 0.002 0.983
Lean body weight kg 48.8 ± 11.1 49.8 ± 11.1 0.002 0.984
Skeletal muscle volume kg 26.3 ± 7.2 26.7 ± 7.0 0.062 0.597
Body fat amount kg 17.6 ± 4.5 17.3 ± 4.8 0.209 0.977
BMI 24.7 ± 2.9 24.7 ± 3.0 0.748 0.999
Body fat percentage % 27.0 ± 6.5 26.1 ± 6.7 0.082 0.614
Waist/hip ratio 0.89 ± 0.04 0.89 ± 0.04 0.135 0.797
Basal metabolism kcal 1325.8 ± 243.2 1344.3 ± 243.7 0.002 0.965
Systolic pressure mmHg 132.3 ± 18.8 126.7 ± 15.8 0.210 0.665
Diastolic pressure mmHg 86.1 ± 13.8 83.0 ± 13.5 0.316 0.972Carnitine Use and Improvements in QOL
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Table 3. Clinical tests of Test Group
n = 18, mean ± SD, paired t test or Mann-Whitney U test
Unit Before 8 weeks later
P value vs 
“before” value
P value vs 
Control Group
Leukocyte Count (WBC) /µl 6051.1 ± 1506.1 6008.9 ± 1717.5 0.841 0.335
Erythrocyte Count (RBC) 104/µl 471.9 ± 33.6 471.9 ± 41.6 0.865
Hemoglobin Content (HGB) g/dl 14.5 ± 1.3 14.6 ± 1.4 0.149 0.497
Hematocrit (HCT) % 44.1 ± 3.3 44.7 ± 3.9 0.183 0.741
Mean Corpuscular Volume (MCV) fl 93.5 ± 3.3 94.8 ± 3.2 0.000 0.736
Mean Corpuscular Hemoglobin (MCH) pg 30.6 ± 1.5 31.0 ± 1.4 0.000 0.270
Mean Corpuscular Hemoglobin 
Concentration (MCHC)
% 32.7 ± 0.9 32.7 ± 0.9 0.568
Platelet count 104/µl 22.5 ± 3.3 22.9 ± 4.1 0.470 0.867
Glutamate Oxaloacetate Transaminase 
(GOT)
U/l 24.6 ± 11.5 23.7 ± 9.9 0.368 0.974
Glutamate Pyruvate 
Transaminase (GPT)
U/l 32.2 ± 30.2 30.2 ± 25.4 0.401 0.992
Alkaline phosphatase (ALP) IU/l 238.7 ± 66.5 227.4 ± 56.6 0.161 0.889
γ-glutamyl transpeptase (γ-GTP) IU/l 59.3 ± 49.8 54.2 ± 47.1 0.236 0.790
Blood Creatinine (Cr) mg/dl 0.68 ± 0.12 0.69 ± 0.13 0.300 0.962
Blood Urea Nitrogen (BUN) mg/dl 13.4 ± 2.8 12.7 ± 2.5 0.274 0.587
Uric acid (UA) mg/dl 5.69 ± 1.42 5.51 ± 1.26 0.235 0.570
Creatine Phosphokinase (CPK) mU/ml 126.4 ± 58.1 123.9 ± 76.6 0.826 0.429
Total cholesterol mg/dl 214.0 ± 31.1 223.7 ± 31.4 0.046 0.887
HDL-cholesterol mg/dl 52.8 ± 12.4 54.4 ± 12.7 0.182 0.525
LDL-cholesterol mg/dl 135.7 ± 29.9 142.3 ± 26.8 0.091 0.691
Triglycerides (TG) mg/dl 144.0 ± 78.1 136.9 ± 68.8 0.546 0.905
Na mEq/l 142.8 ± 1.5 143.2 ± 1.1 0.130 0.983
K mEq/l 4.19 ± 0.37 4.16 ± 0.28 0.622 0.882
Cl mEq/l 104.9 ± 2.1 104.8 ± 1.7 0.915 0.905
Fasting Blood Sugar (FBS) mg/dl 91.9 ± 10.6 95.7 ± 7.5 0.016 0.615
Glycohemoglobin A1C (HbA1c) % 4.73 ± 0.43 4.89 ± 0.39 0.000 0.799
C-Reactive Protein (CRP) mg/dl 0.22 ± 0.15 0.21 ± 0.14 0.870 0.685
Lactic acid mg/dl 9.54 ± 5.83 8.52 ± 3.17 0.279 0.471
Lipid peroxide (LPO) nmol/ml 0.39 ± 0.07 0.34 ± 0.08 0.001 0.802
Insulin µU/ml 7.56 ± 4.12 8.33 ± 3.87 0.364 0.648
IGF-I ng/ml 185.3 ± 42.9 175.1 ± 31.3 0.160 0.636
Cortisol µg/dl 11.4 ± 5.0 9.4 ± 4.0 0.071 0.562
Dehydroepiandrosterone 
Sulfate (DHEA-s)
ng/ml 1600.1 ± 792.2 1589.1 ± 979.9 0.928 0.993
8-hydroxy-deoxyguanosine 
(8-OHdG) generation
ng/kg/hr 8.78 ± 5.2 7.46 ± 4.63 0.186 0.549
Isoprostane generation ng/kg/hr 145.2 ± 73.8 114.4 ± 69.6 0.060 0.427
8-OHdG/CRE ng/mgCRE 126.0 ± 65.3 126.5 ± 90.2 0.488 0.353
Isoprostane/CRE ng/mgCRE 1977.2 ± 848.0 1631.5 ± 635.9 0.054 0.338Y. Yonei et al.
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Table 4. Clinical tests of Control Group
n = 17, mean ± SD, paired t test or Mann-Whitney U test
Unit Before 8 weeks later
P value vs 
“before” value
P value vs 
Test Group
Leukocyte Count (WBC) /µl 7244.0 ± 2665.9 6456.7 ± 2120.0 0.020 0.335
Erythrocyte Count (RBC) 104/µl 468.6 ± 40.0 464.7 ± 42.0 0.477 0.865
Hemoglobin Content (HGB) g/dl 14.2 ± 1.6 14.2 ± 1.7 0.768 0.497
Hematocrit (HCT) % 43.3 ± 3.7 43.4 ± 3.8 0.863 0.741
Mean Corpuscular Volume (MCV) fl 92.6 ± 5.6 93.5 ± 5.7 0.038 0.736
Mean Corpuscular Hemoglobin (MCH) pg 30.4 ± 2.6 30.5 ± 2.7 0.293 0.270
Mean Corpuscular Hemoglobin 
Concentration (MCHC)
% 32.8 ± 1.3 32.6 ± 1.3 0.309 0.568
Platelet count 104/µl 26.4 ± 4.5 26.5 ± 5.6 0.810 0.867
Glutamate Oxaloacetate Transaminase 
(GOT)
U/l 23.4 ± 5.3 22.3 ± 5.5 0.408 0.974
Glutamate Pyruvate 
Transaminase (GPT)
U/l 27.3 ± 11.3 26.3 ± 11.0 0.618 0.992
Alkaline phosphatase (ALP) U/l 251.3 ± 71.2 244.0 ± 63.8 0.443 0.889
γ-glutamyl transpeptase (γ-GTP) U/l 49.1 ± 40.2 50.7 ± 47.7 0.736 0.790
Blood Creatinine (Cr) mg/dl 0.68 ± 0.15 0.69 ± 0.15 0.241 0.962
Blood Urea Nitrogen (BUN) mg/dl 14.3 ± 3.7 14.2 ± 2.6 0.923 0.587
Uric acid (UA) mg/dl 5.59 ± 1.26 5.64 ± 1.14 0.799 0.570
Creatine Phosphokinase (CPK) mg/dl 138.6 ± 91.0 183.9 ± 251.4 0.327 0.429
Total cholesterol mg/dl 224.6 ± 47.2 230.5 ± 50.8 0.346 0.887
HDL-cholesterol mg/dl 51.5 ± 7.8 55.6 ± 11.2 0.069 0.525
LDL-cholesterol mg/dl 147.6 ± 46.3 148.1 ± 43.7 0.910 0.691
Triglycerides (TG) mg/dl 173.4 ± 147.7 132.3 ± 57.7 0.259 0.905
Na mEq/l 142.4 ± 1.2 142.9 ± 1.2 0.150 0.983
K mEq/l 4.21 ± 0.30 4.13 ± 0.26 0.395 0.882
Cl mEq/l 104.1 ± 1.6 104.4 ± 2.0 0.658 0.905
Fasting Blood Sugar (FBS) mg/dl 92.9 ± 9.4 94.3 ± 10.3 0.576 0.615
Glycohemoglobin A1C (HbA1c) % 4.89 ± 0.40 5.03 ± 0.43 0.001 0.799
C-Reactive Protein (CRP) mg/dl 0.19 ± 0.10 0.17 ± 0.11 0.262 0.685
Lactic acid mg/dl 8.17 ± 3.45 9.56 ± 3.51 0.173 0.471
Lipid peroxide (LPO) nmol/ml 0.65 ± 0.99 0.32 ± 0.08 0.216 0.802
Insulin µU/ml 9.00 ± 7.13 7.93 ± 3.83 0.543 0.648
IGF-I ng/ml 197.9 ± 68.9 180.6 ± 60.4 0.007 0.636
Cortisol µg/dl 9.9 ± 3.0 10.2 ± 6.8 0.873 0.562
Dehydroepiandrosterone 
Sulfate (DHEA-s)
ng/ml 2034.1 ± 1136.3 1928.3 ± 899.5 0.474 0.993
8-hydroxy-deoxyguanosine 
(8-OHdG) generation
ng/kg/hr 9.45 ± 7.41 8.85 ± 4.59 0.282 0.549
Isoprostane generation ng/kg/hr 142.2 ± 88.7 138.1 ± 85.5 0.336 0.427
8-OHdG/CRE ng/mgCRE 116.0 ± 73.9 128.5 ± 71.7 0.233 0.353
Isoprostane/CRE ng/mgCRE 1846.1 ± 869.6 1837.8 ± 1117.4 0.377 0.338Carnitine Use and Improvements in QOL
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count, hemoglobin content, hematocrit, GPT, γ-GTP, creati-
nine, and uric acid levels. Special tests such as hormone
levels showed that men had significantly higher values than
women in terms of cortisol (p<0.05) and DHEA-s (p<0.05).
In oxidation stress marker tests, men showed a significantly
higher 8-OHdG/CRE value than did the women. However,
none of the other items showed any gender differences.
Improvement rates of oxidation stress markers before and
after the tests showed no gender differences.
Variations associated with aging
A correlational analysis was performed between chrono-
logical age and each test item. Regarding the results of
physical measurement, height, weight, body water content
and muscle volume, lean muscle mass, skeletal muscle
volume and basal metabolism, they were lower with
advanced age (p<0.01), while body fat percentage and
waist/hip ratio was higher with respect to age (p<0.05).
Regarding general laboratory test items, those that rose with
age were creatinine (p<0.01), uric acid (p<0.05) and HDL-C
Table 5. Physical symptoms of Test Group
n = 18, mean ± SD, paired t test or Mann-Whitney U test
Before 8 weeks later
P value vs 
“before” value
P value vs 
Control Group
Tired eyes 3.1 ± 1.0 2.6 ± 1.0 0.015 0.826
Blurry eyes 2.5 ± 0.9 2.0 ± 1.0 0.035 0.122
Eye pain 1.9 ± 0.9 1.6 ± 0.8 0.135 0.360
Stiff shoulders 3.6 ± 1.2 3.2 ± 1.3 0.138 0.992
Muscle pain/stiffness 3.4 ± 1.3 2.8 ± 1.3 0.017 0.277
Palpitations 1.7 ± 0.8 1.7 ± 0.8 0.579 0.692
Dyspnea 1.9 ± 0.9 1.7 ± 0.8 0.135 0.171
Tendency to gain weight 3.9 ± 0.9 3.7 ± 0.9 0.361 0.861
Weight loss; thin 1.2 ± 0.4 1.1 ± 0.3 0.331 0.343
Lethargy 2.9 ± 1.0 2.4 ± 1.0 0.134 0.403
No feeling of good health 2.3 ± 1.0 2.2 ± 0.9 0.528 0.655
Thirst 1.9 ± 0.8 1.9 ± 1.0 0.895
Skin problems 2.3 ± 1.3 2.3 ± 1.2 0.728
Anorexia 1.7 ± 0.8 1.5 ± 0.8 0.331 0.988
Early satiety 1.9 ± 0.9 1.5 ± 0.9 0.042 0.314
Epigastralgia 1.8 ± 0.8 1.4 ± 0.7 0.010 0.293
Liable to catch colds 2.0 ± 1.0 2.1 ± 1.0 0.842 0.977
Coughing and sputum 2.2 ± 1.1 2.3 ± 1.1 0.528
Diarrhea 2.1 ± 0.6 2.0 ± 0.9 0.772 0.432
Constipation 2.2 ± 1.2 2.2 ± 1.2 0.749 0.998
Headache 2.1 ± 0.8 2.2 ± 0.9 0.790 0.624
Dizziness 1.8 ± 0.7 1.3 ± 0.5 0.003 0.008
Tinnitus 1.9 ± 0.8 1.7 ± 1.0 0.104 0.086
Lumbago 3.2 ± 1.2 2.7 ± 1.0 0.088 0.353
Arthralgia 2.7 ± 1.0 2.2 ± 0.8 0.037 0.257
Edematous 2.6 ± 1.2 2.6 ± 1.1 0.908
Easily beaking into a sweat 3.8 ± 1.1 3.0 ± 1.3 0.026 0.310
Frequent urination 2.4 ± 1.1 2.4 ± 1.3 0.859 0.727
Hot flashes 1.9 ± 1.0 1.8 ± 1.0 0.834 0.992
Excessive sensitivity to cold 2.1 ± 1.0 2.3 ± 1.1 0.260 0.944Y. Yonei et al.
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(p<0.05), but HbA1c decreased with age (p<0.01). Tests
for hormones showed that DHEA-s decreased with age
(p<0.01). As for oxidation stress markers, the volume of 8-
OHdG production decreased with age (p<0.05), as did 8-
OHdG/CRE (p<0.01), while the improvement rates of 8-
OHdG/CRE dropped with age (p<0.05). Of the Anti-Aging
QOL Common Questionnaire (AAQol) items, among phys-
ical symptoms, scores for “anorexia” and “excessive sensi-
tivity to cold” increased with age (p<0.05). Regarding
mental symptoms, the score for “shallow sleep” increased
with age (p<0.05).
Variations between test items
Items in which the Test Group showed significant changes
before and after the test, namely, total cholesterol, fasting
blood sugar, HbA1c, lipid peroxide, “tired eyes,” “blurry
eyes,” “muscle pain/stiffness,” “early satiety,” “epigastric
pain,” “dizziness,” “arthralgia” and “easily breaking into a
sweat,” we studied the factors that influenced the change
rates. Total cholesterol’s degree of change increased in
Table 6. Physical symptoms of Control Group
n = 17, mean ± SD, paired t test or Mann-Whitney U test
Before 8 weeks later
P value vs 
“before” value
P value vs 
Test Group
Tired eyes 2.7 ± 0.8 2.5 ± 1.1 0.582 0.826
Blurry eyes 2.1 ± 0.9 2.2 ± 0.9 0.610 0.122
Eye pain 1.7 ± 0.7 1.8 ± 0.9 0.582 0.360
Stiff shoulders 3.6 ± 0.9 3.3 ± 0.9 0.217 0.992
Muscle pain/stiffness 2.7 ± 1.3 2.5 ± 1.0 0.424 0.277
Palpitations 1.7 ± 0.8 1.7 ± 0.9 0.692
Dyspnea 1.8 ± 0.9 1.9 ± 0.9 0.634 0.171
Tendency to gain weight 3.2 ± 1.1 3.1 ± 0.9 0.499 0.861
Weight loss; thin 1.5 ± 0.6 1.6 ± 0.5 0.334 0.343
Lethargy 2.5 ± 1.2 2.6 ± 1.1 0.774 0.403
No feeling of good health 2.5 ± 0.9 2.1 ± 1.1 0.207 0.655
Thirst 2.1 ± 1.1 2.0 ± 0.8 0.634 0.895
Skin problems 2.4 ± 1.1 2.4 ± 1.5 0.728
Anorexia 1.8 ± 0.6 1.7 ± 0.5 0.164 0.988
Early satiety 1.9 ± 0.8 2.0 ± 0.8 0.433 0.314
Epigastralgia 1.8 ± 0.9 1.8 ± 0.7 0.293
Liable to catch colds 1.9 ± 0.9 1.9 ± 0.7 0.751 0.977
Coughing and sputum 1.9 ± 0.9 2.1 ± 0.7 0.104
Diarrhea 2.1 ± 0.9 2.2 ± 0.8 0.610 0.432
Constipation 2.1 ± 1.2 2.0 ± 1.0 0.670 0.998
Headache 2.3 ± 1.3 2.1 ± 1.0 0.262 0.624
Dizziness 1.5 ± 0.9 1.7 ± 0.7 0.104 0.008
Tinnitus 1.6 ± 0.9 1.8 ± 0.9 0.189 0.086
Lumbago 2.7 ± 1.6 2.7 ± 1.2 0.774 0.353
Arthralgia 2.0 ± 1.2 2.1 ± 1.0 0.865 0.257
Edematous 2.3 ± 1.0 2.2 ± 0.7 0.818 0.908
Easily breaking into a sweat 2.8 ± 1.3 2.7 ± 1.1 0.653 0.310
Frequent urination 1.7 ± 0.9 1.8 ± 0.7 0.774 0.727
Hot flashes 1.9 ± 0.9 1.8 ± 0.6 0.546 0.992
Excessive sensitivity to cold 2.0 ± 1.3 2.3 ± 1.0 0.217 0.944Carnitine Use and Improvements in QOL
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correlation to the number of cigarettes smoked (r =0 . 3 7 ,
p<0.05). The lower the insulin values (r = –0.50, p<0.01)
and 8-OHdG/CRE values (r = –0.36,  p<0.01), the higher
the degree of change of fasting blood sugar. Women showed
a high increase rate of HbA1c (p<0.05). The degree of
change in lipid peroxides tended to decrease in women
(p<0.01), in young people (r = –0.37,  p<0.01), in those
with a high alcohol consumption (p<0.05), in those with
high cortisol levels (r = –0.35, p<0.05), and in those with
high values for height, body water content, muscle volume,
lean muscle mass, skeletal muscle volume, and body fat, as
well as those with high blood pressure (r = 0.46, p<0.05).
The improvement in scores for “tired eyes” was most
marked in subjects with high cortisol values (r = −0.38,
p<0.05), and in subjects who were extremely “irritable”
(r = –0.38,  p<0.05) or “easily angered/short-tempered”
(r = –0.35,  p<0.05). The degree of change in scores for
“blurry eyes” was most marked in subjects with low insulin
levels (r = 0.36, p<0.05) and low diastolic pressure (r =0 . 3 7 ,
p<0.05). The improvement in scores for “muscle pain/stiff-
ness” was most marked in younger subjects (r =0 . 4 4 ,
p<0.05), but less so for subjects with “shallow sleep”
(r =0 . 4 3 ,  p<0.05). Scores for “early satiety” (r =0 . 4 2 ,
p<0.05) and “epigastric pain” (r = 0.51, p<0.01) tended to
improve less readily in subjects with “shallow sleep.” There
were no factors that affected the improvement rates in the
score for “dizziness.” The improvement in score for
“arthralgia” was most marked in heavy smokers (r = −0.36,
p<0.05), subjects who were “irritable” (r = −0.39, p<0.05),
“easily angered/short-tempered” (r = −0.35,  p<0.05), or
“depressed” (r = −0.38,  p<0.05). The scores tended to
improve less in those who engaged in regular and vigorous
exercise (r =0 . 5 3 ,  p<0.05). The degree of improvement in
the scores for “easily breaking into a sweat” tended to be low
in subjects with high cortisol values (r = −0.36, p<0.05), but
was higher in subjects who had a “loss of motivation”
Table 7. Mental symptoms of Test Group
n = 18, mean ± SD, paired t test or Mann-Whitney U test
Before 8 weeks later
P value vs 
“before” value
P value vs 
Control Group
Irritability 2.7 ± 0.8 2.6 ± 1.1 0.651 0.348
Easily angered/short-tempered 2.6 ± 0.9 2.5 ± 1.1 0.651 0.131
Loss of motivation 2.6 ± 1.1 2.1 ± 1.1 0.058 0.985
No feeling of happiness 2.0 ± 1.0 2.0 ± 1.1 0.983
Nothing to look forward to in life 2.0 ± 1.2 1.8 ± 0.9 0.386 0.926
Daily life is not enjoyable 2.1 ± 1.0 2.0 ± 0.9 0.717 0.800
Lose of confidence 1.7 ± 0.8 1.7 ± 0.9 0.749 0.911
Reluctance to talk with others 2.2 ± 0.9 1.7 ± 0.8 0.057 0.573
Depressed 2.0 ± 0.9 1.9 ± 1.0 0.542 0.909
A feeling of uselessness 1.8 ± 0.7 1.8 ± 0.9 0.831
Shallow sleep 2.2 ± 0.9 2.1 ± 1.2 0.528 0.998
Difficulty falling asleep 1.8 ± 0.9 1.7 ± 0.8 0.269 0.708
Pessimism 2.3 ± 0.8 2.2 ± 1.0 0.421 0.834
Lapse of memory 2.9 ± 0.9 2.8 ± 1.2 0.430 0.706
Inability to concentrate 2.3 ± 1.2 2.3 ± 1.0 0.790 0.849
Inability to solve problems 2.1 ± 1.1 1.9 ± 1.0 0.163 0.499
Inability to make judgements 
readily
2.1 ± 1.0 1.9 ± 1.0 0.163 0.315
Inability to sleep because of wor-
ries
1.7 ± 0.7 1.9 ± 1.0 0.331 0.214
A sense of tension 2.1 ± 0.9 2.4 ± 0.9 0.083 0.065
Feeling of anxiety for no special 
reason
1.6 ± 0.6 1.6 ± 0.5 0.717 0.772
Vague feeling of fear 1.6 ± 0.7 1.7 ± 0.6 0.772 0.842Y. Yonei et al.
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(r =0 . 4 1 ,   p<0.05).
Discussion
Amino acids
A healthy individual with a standard weight of 60 kg is
said to require about 2,000 to 2,400 kcal per day, with the
ratio among carbohydrates, protein and fat ideally being
6:2:2. The ideal daily protein intake, moreover, is said to be
within the range of 80 to 120 g. We await more investiga-
tions on the optimal doses based on EBM. It is recom-
mended that between 5 and 10 g of amino acids be
replenished in the form of amino acid supplements if
individuals fail to meet the required protein intake level due
to eating irregularly, or if their masticatory capabilities
have weakened [1].
In the course of protein being synthesized from amino
acids in vivo, it requires the aid of vitamin B6 and other
substances. Antioxidants such as vitamin C and E are also
useful in suppressing the free radicals that develop during
this process.
The human body is composed of 20 types of amino acids.
There are ten amino acids that cannot be synthesized in vivo
and therefore must be obtainable from food: valine, leucine,
isoleucine, histidine, phenylalanine, tryptophan, lysine,
methionine, arginine, and threonine. There are ten nonessen-
tial amino acids that can be synthesized in vivo: glutamine,
proline, glycine, asparagine, glutamic acid, aspartic acid,
cysteine, tyrosine, serine, and alanine.
The synthetic capability in vivo of nonessential amino
acids generally declines with age. What is especially impor-
tant is not chronological age, but hormonal age, as revealed
in a reduction in DHEA, growth hormones and IGF-I.
Growth hormones and IGF-I directly affect amino acid
synthesis, and decreased DHEA that is synthesized in the
adrenal gland indirectly affects the synthesis of amino acids
Table 8. Mental symptoms of Control Group
n = 17, mean ± SD, paired t test or Mann-Whitney U test
Before 8 weeks later
P value vs 
“before” value
P value vs 
Test Group
Irritability 2.3 ± 1.0 2.5 ± 0.6 0.433 0.348
Easily angered/short-tempered 2.3 ± 1.1 2.5 ± 0.6 0.384 0.131
Loss of motivation 2.3 ± 0.8 2.0 ± 0.7 0.055 0.985
No feeling of happiness 2.2 ± 0.8 2.1 ± 0.7 0.774 0.983
Nothing to look forward to in life 2.1 ± 0.9 1.9 ± 0.5 0.499 0.926
Daily life is not enjoyable 2.3 ± 0.8 2.0 ± 0.5 0.217 0.800
Lose of confidence 2.3 ± 0.8 1.9 ± 0.5 0.173 0.911
Reluctance to talk with others 1.9 ± 0.8 1.9 ± 0.7 0.573
Depressed 2.1 ± 0.8 2.1 ± 0.7 0.774 0.909
A feeling of uselessness 2.1 ± 0.5 2.1 ± 0.5 0.831
Shallow sleep 2.5 ± 1.1 2.3 ± 0.9 0.189 0.998
Difficulty falling asleep 2.3 ± 1.0 1.9 ± 0.7 0.019 0.708
Pessimism 2.6 ± 1.0 2.2 ± 0.7 0.054 0.834
Lapse of memory 2.9 ± 0.7 2.9 ± 0.6 0.706
Inability to concentrate 2.2 ± 0.7 2.3 ± 0.6 0.582 0.849
Inability to solve problems 2.1 ± 0.5 2.2 ± 0.7 0.334 0.499
Inability to make judgements 
readily
2.2 ± 0.8 2.3 ± 0.6 0.774 0.315
Inability to sleep because 
of worries
2.4 ± 1.0 2.1 ± 0.8 0.136 0.214
A sense of tension 2.4 ± 0.6 2.3 ± 0.7 0.433 0.065
Feeling of anxiety for no special 
reason
1.9 ± 0.9 1.8 ± 0.6 0.499 0.772
Vague feeling of fear 1.7 ± 0.6 1.7 ± 0.7 0.842Carnitine Use and Improvements in QOL
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and proteins via reductions in protein-synthesizing hor-
mones that are synthesized based on DHEA and in andro-
gens that have protein anabolic activity.
Carnitine
Carnitine is a type of amino acid. L-carnitine works to
combine with acyl-CoA that is generated intracellularly
from free fatty cells to produce acylcarnitine and to enable
the passage of acyl-CoA through endosporium of mitochon-
dria [8–13]. Therefore, it is essential to the metabolism of
intracellular fat; it also works to reduce the dependence of
the body on sugar as a source of energy. It protects against
degeneration of nerve cells, so it is believed to be useful for
preventing loss of short-term memory, Alzheimer’s disease,
and depression [11]. There are also reports that carnitine
helps in the treatment of liver and heart diseases [13], of
male reproductive functions and mental stress [10] and in
restoring visual acuity. It also has the potential to reduce the
levels of lipids circulating within the blood and thus lower
the risk of arteriosclerosis [13]. Deficiency in carnitine
induces impaired intracellular fat metabolism [8]. Foods that
contain abundant carnitine include mutton and beef.
A study that measured the amount of carnitine in the
plasma and the liver of 68 pediatric chronic liver disease and
36 cirrhosis patients showed that the latter patients had low
plasma carnitine concentrations [14]. Meanwhile, in a study
using 382 hyperlipidemia patients taking statin drugs (167
males and 215 females; mean age: 63.17 years), patients
given oral statins had higher CPK levels than normal popu-
lations, and had significantly lower plasma acylcarnitine
levels. This suggests the possibility that, for some unknown
reason, individuals on oral statin drugs have fatty acid
metabolic abnormalities due to abnormal carnitine metabo-
lism, and that this may be one of the causes of the rise in
CPK levels and myopathy [15].
Carnitine in animal models
Carnitine influences metabolic mechanisms in numerous
ways. A study in which 200 mg/kg of L-carnitine was
administered for 4 weeks to streptomycin-induced diabetic
rats showed that the drug helped to restore serum IGF-I to
close to normal concentrations [16]. In septic rats that had
undergone appendix ligation and perforation, the concentra-
tion of endotoxins in the blood rose, while the concentra-
tions of branched chain amino acids in the blood (leucine,
isoleucine and valine) as well as glutamine were lower.
Administration of L-carnitine, however, is shown to sup-
press declines in the concentrations of branched-chain
amino acids and glutamine [17]. Aged rats, in particular,
show decreases in the content of protein in each tissue as
well as the level of protein-bound hexose, hexosamine, sialic
acid, and fucose. However, intra-abdominal administration
of L-carnitine is shown to improve the conditions of these
glycoproteins. On the other hand, in young rats, the admin-
istration of L-carnitine does not induce these changes,
suggesting that carnitine helps in normalizing age-induced
changes in glycoproteins [18].
Carnitine also affects the gastrointestinal tract. There is a
reduction in gastric mucins and prostaglandin E2 of rats
subjected to cold stress. However, the administration of
L-carnitine suppresses this reduction as well as the develop-
ment of gastric mucosal lesions and formation of lipid
peroxide. Administration of L-carnitine is also shown to
elevate catalase activity in the blood and inside the gastric
mucosal membrane [19].
Carnitine also acts on the sensory organs. In a study in
which palmitoyl-DL-carnitine (1 × 10−4 M) was admin-
istered to guinea pigs via perilymphatic reflux, measure-
ments of the endocochlear DC potential and cochlear micro-
phonics showed the former to have dropped to +8 ~ +16 mV,
and the latter to 30 ~ 39%, suggesting a direct effect of
palmitoyl-DL-carnitine on cochlear hair cells [20].
Several reports have been published on the effects of
carnitine on the heart. Administration of adriamycin reduces
free carnitine in rat cardiac muscle and boosts acylcarnitine
levels. These, however, were shown to improve after 500
mg/kg of L-carnitine was administered intra-abdominally
on a daily basis, showing that L-carnitine counteracts
cardiotoxicity of adriamycin [21]. In a study using rat
models of ischemic myocardial disorders, administration of
L-carnitine prior to re-reflux was shown to increase free
carnitine, activating fatty acid metabolism after re-reflux
and improving glycolytic metabolism that was impaired
because of ischemia, thereby improving myocardial metabo-
lism and promoting the recovery of myocardial function
[22]. In another study that investigated the effects of L-
carnitine in which extracted reflux heart of diabetic rats
(a state of diabetic cardiac dysfunction such as reduction in
systolic and diastolic functions) was used, reduced intra-
myocardial carnitine content was seen to improve with
oral administration of propionyl-L-carnitine. The drug also
increased intra-myocardial carnitine and improved cardiac
function [23].
Clinical effects of carnitine
Initially, reports on the activity of carnitine in humans
mostly focused on cardiac function. In a study in which
200 mg/day of L-carnitine was administered to nine patients
with heart disease (i.e., history of myocardial infarction)
after undergoing ergometer exercise tests, the subjects
showed improvements in exercise time peak value and
maximum oxygen consumption volume, as well as higher
lactic acid and ventilation thresholds. L-carnitine was there-
fore shown to improve loss of exercise tolerance [24]. In a
study in which L-carnitine was administered orally for 12
weeks, exercise tolerance significantly improved in exer-Y. Yonei et al.
J. Clin. Biochem. Nutr.
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tional angina patients, while 5 out of 9 chronic congestive
heart failure patients were switched to a less severe NYHA
class category, and 6 patients saw their systemic conditions
improve [25]. In a study in which 60 mg/kg of levocarnitine
was administered via intravenous drip to 15 ischemic heart
disease patients, myocardial metabolism and blood flow in-
crease during exercise were stepped up, indicating that the
drug demonstrated anti-angina activity [26]. In a study that
compared the effects of levocarnitine chloride and a placebo
in 46 stable, exertional angina patients, administration of
levocarnitine was shown to extend the time of exercise in
multiple-stage treadmill exercise tests and prolong the time
to onset of angina pain [27]. Meanwhile, a multi-center,
double-blind, placebo-controlled intra-group comparative
test was performed, targeting 114 angina patients who still
suffered angina pain despite administration of timed-released
nitric acid drugs. A combination of timed-released nitric acid
drugs and levocarnitine chloride was used. As a result,
compared with the Control Group, the Levocarnitine Group
saw significant improvements in their exercise ECG [28].
Levocarnitine preparations are used today as L-Cartin®,
a drug covered by Japanese health insurance.
There are also reports on the use of L-carnitine as a
dietary supplement for patients with renal failure. In a
study of 17 hemodialysis patients who were undergoing
continuous maintenance therapy comprising erythropoietin,
the maintenance dosage of erythropoietin correlated nega-
tively to serum free carnitine concentration. Twenty weeks
after taking 500 mg/day of carnitine chloride, four patients
saw an over 20% improvement in their hematocrit values,
three of whom were able to reduce the dose of erythropoietin
[29]. In a study targeting 7 chronic renal failure patients
undergoing hemodialysis (mean: 61 ± 17 years, mean
history of dialysis: 17 ± 10 years), as a result of administra-
tion of L-carnitine (1,000 mg/day for the first month and
500 mg/1–2 days after the second month; the drug was con-
tinued for 2 or more years), serum total carnitine concentra-
tion improved, the dose of erythropoietin could be
decreased, and palpitations as well as post-dialysis fatigue
and lethargy improved. These results suggest that dietary
supplementation with L-carnitine is useful for improving the
QOL of dialysis patients [30].
Recently, reports related to supplements containing
carnitine have also been published. In an open test in which
ten healthy individuals (4 males; mean age, 40.0 ± 4.2 years;
BMI, 27.2 ± 2.2; 6 females; mean age, 35.2 ± 9.4 years;
BMI, 26.9 ± 2.8) took Metabolic L-Carnitine Plus® for 40
days, both men and women saw a significant reduction in
weight, BMI, body fat percentage, bust, waist, hip, upper
arm, thigh, and calf circumference; a significant rise in total
carnitine, free carnitine, and acylcarnitine; and a significant
drop in total cholesterol, triglycerides, blood sugar and lactic
acid. The results show the potential usefulness of supple-
ments containing carnitine in promoting lipolysis and energy
production in obese individuals [31].
Garcinia cambogia extract
Hydroxycitric acid is a major acid component of the
tropical plants Garcinia cambogia [32]. (2S, 3S)-HCA from
G. cambogia was shown to be a potent inhibitor of ATP
citrate lyase, which catalyzes the extramitochondrial
cleavage of citrate to oxaloacetate and acetyl-CoA. HCA
used in dietary weight loss supplement. In the present study,
500 mg/day of hydroxycitric acid had no significant effect
on the body component. The dietary efficacy was not
indicated.
Results of our tests
Results of the analysis of the Common Questionnaire
(AAQol) showed that the Test Group revealed significant
improvements in a number of physical symptoms. This is
believed to be attributable to the comprehensive actions of
amino acids and multiple vitamins contained in the Product.
Improvement effects on “dizziness,” in particular, showed
significant differences between the Test Group and the
Control Group, indicating that the Product significantly
improved “dizziness.” This is also believed to be related to
the direct activity of carnitine on cochlear hair cells [20].
Among the Test Group, symptoms such as “early satiety”
and “epigastric pain” improved significantly. Carnitine is
known to improve digestive tract movements and to
suppress lesions in the gastric mucosal membrane [19], so it
is believed to be involved in improving both “early satiety”
and “epigastric pain.”
Regarding ocular symptoms, a number of reports have
been released. One states that there was a reduction in
carnitine inside the ocular lens of diabetic rats [33], while
another found carnitine to be effective for ischemic re-reflux
disorder in the retina of guinea pigs [34]. There is also a
report of a clinical test with human subjects that showed a
supplement containing carnitine to counter macular degen-
eration [35]. The fact that ocular symptoms such as “tired
eyes” and “blurry eyes” significantly improved in the Test
Group may be attributable to this recovery of the concentra-
tion of carnitine in the ocular tissue.
In our laboratory tests, a significant rise was seen in total
cholesterol, fasting blood sugar, and HbA1c. Although past
reports have shown that carnitine corrects lipid and sugar
metabolism [8, 10, 13], our test produced a different result,
showing that “early satiety” and “epigastric pain” were
alleviated, so it is highly likely that other elements may have
come into play, such as increased appetite and improved
caloric intake from food. As for oxidation stress markers,
lipid peroxides decreased significantly in the Test Group.
Carnitine plays an important role in lipid metabolism [8] and
possesses anti-oxidation activity [19,  22,  34,  36], so aCarnitine Use and Improvements in QOL
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decrease in lipid peroxides is not contradictory.
These findings suggest that the consumption of the
supplement can reduce the oxidative damage and some
symptoms in the human; however, the effect on QOL was
equivocal from the results of the effect on lipid metabolism.
Garcinia cambogia extract did not show dietary efficacy.
Muscular fatigue
If a person undergoes muscular load training for 15 min-
utes, lactic acid is produced in the muscular tissues; 30 min-
utes later, growth hormone-reactive secretion peaks from the
pituitary gland. Two hours after the start of exercise, fat
breaks down, and the concentration of free fatty acid in the
blood peaks [2]. In individuals engaging in aerobic exercises
such as jogging and aerobics, glucose and fatty acids enter
the TCA circuit, which is one of the body’s energy-
producing systems, to generate energy. In contrast, in anaero-
bic exercises, such as weightlifting, lactic acid is generated
without having glucose and fatty acids enter the TCA circuit.
Although lactic acid is a factor that encourages the secretion
stimulation of growth hormones, it can also cause muscular
pain and fatigue.
In our test, scores for “muscle pain/stiffness” changed
from 3.4 ± 1.3 to 2.8 ± 1.3 (−17.6%, p= 0.017) in the Test
Group, and from 2.7 ± 1.3 to 2.5 ± 1.0 (−7.4%) in the
Control Group, showing no significant differences in the
improvement rate between the two groups. However, it
improved significantly in the Test Group only. An important
activity of carnitine is that it combines with acyl-CoA,
which is produced from free fatty acids inside the cells, to
enable the passage of acyl-CoA through the mitochondrial
endosporium [8–13]. This is most likely because, even in
muscle cells, which are packed with mitochondria,
replenishing carnitine improves the status of metabolism to
bring about favorable effects.
Correlations between test items
Administration of the Product induced significant
changes in total cholesterol, fasting blood sugar, HbA1c, and
lipid peroxide, as well as symptoms such as “tired eyes,”
“blurry eyes,” “muscle pain/stiffness,” “early satiety,”
“epigastric pain,” “dizziness,” “arthralgia,” and “easily
breaking into a sweat.”
The fact that total cholesterol increases in proportion
to the number of cigarettes smoked implies that total
cholesterol and smoking, which are risk factors for arterio-
sclerosis, may work synergistically. This reconfirms the im-
portance of reducing these risk factors one by one to prevent
diseases related to arteriosclerosis such as cerebral apoplexy
and heart disease. We were not able to identify the relation-
ship between the degree of change in fasting blood sugar and
insulin values and 8-OHdG/CRE.
Lipid peroxides are believed to be relatively high in
women who have high body fat percentages, in young
people who drink heavily, and in individuals with high
values for height, body water content, muscle volume, lean
muscle mass, and skeletal muscle volume; these values are
liable to drop because of antioxidative substances contained
in the Product. It appears, however, that elderly individuals
do not demonstrate antioxidative effects very readily. The
relationship with cortisol is not clear.
Individuals who have high cortisol values, and who show
extreme “irritability” or who are “easily angered/short-
tempered” are believed to suffer extensive “tired eyes.” It
may be that it was relatively easy to see their symptoms
related to “tired eyes” improve because of the Product. The
causal relationship between the degree of change in the
scores for “blurry eyes,” insulin value and diastolic blood
pressure is not clear. It appears that the older the individual,
the more difficult for his or her “muscle pain/stiffness” to
improve; the more a person suffers “shallow sleep,” the
more difficult for it to improve because of insufficient tissue
restoration during sleep. It appears that symptoms of “early
satiety” and “epigastralgia” are difficult to improve in
individuals who often experience “shallow sleep.” This
suggests the importance of sleep. Heavy smokers and people
who have major symptoms of “irritability”, “easily angered/
short-tempered,” and being depressed tend to manifest
symptoms of “arthralgia” more strongly than others, so it
may be that these symptoms tend to improve more readily as
a result of using the Product. People who exercise exten-
sively to begin with have their “arthralgia” already in a
steady state, so it may be that their symptoms do not change
very readily, even as a result of using the Product. We were
unable to identify any relationship between “easily breaking
into a sweat” and cortisol value or “loss of motivation.”
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